skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

30 Total results for product and free and sample content found

In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

How To Obtain Effective Relief When A Global Pandemic Disrupts Your Supply Chain

The COVID-19 pandemic is disrupting global supply chains and companies need effective tools to manage the related contract disputes. Sidley Austin partner Dorothee Schramm and senior associate Katie von der Weid, both specialized in international commercial disputes, provide tips to help companies manage the situation.

Topic Coronavirus Business Strategies Deals

In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

In Vivo Deal Making Article Pack

In Vivo Deal Making Article Pack

Gain a view into the market gaps, opportunities, and trends in biopharma with a look at deal-making from In Vivo. Examine how deal-making has impacted the industry and shifted market dynamics and learn how you can use knowledge of these trends to inform your own strategies.

Generics Bulletin: ジェネリック&バイオシミラーニュース

Sun Finds US ‘Challenging’

Sun Pharma’s Indian domestic operations posted strong sales in the third quarter, but this was not enough to prevent the company from reporting a 26% tumble in consolidated net profit in the face of a “challenging” US generics market and slow approvals for complex products.

Topic deal-trends

Generics Bulletin: ジェネリック&バイオシミラーニュース

Coherus Is Confident After US Ranibizumab Filing

Coherus_Is_Confident_After_US

Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.

Topic Biosimilars Deal trends

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

J.P. Morgan Conference Updates

Updates and coverage of the 2020 J.P. Morgan Healthcare Conference in San Francisco.

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Korea 2020 Outlook: Hopes Of Turnaround Amid Potential Deals, Biosimilar Launches, Biologics Law

After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.

Topic clinical-trials deal-trends

Generics Bulletin: ジェネリック&バイオシミラーニュース

Biocon Biologics Gets True North Investment

Biocon_Biologics_Gets_True_North_Investment

Private equity group True North continues to back the Biocon group and is picking up a minority stake in Biocon Biologics in a deal that values the subsidiary at $3bn. Separately, another subsidiary, Biocon Biosphere, has also been set up as part of efforts to unlock the full potential of the business.

Topic deal-trends strategy

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

J.P. Morgan 2020: What To Watch For At The Industry's Biggest Meeting

The J.P. Morgan Healthcare conference is being held a week later than usual, which only makes us more ready to hear what the industry's leaders have in store. Here's a preview of potential hot topics.

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Novartis Sees Reimbursement Advantage For PCSK9 Launch

Administration under the medical benefit/Medicare Part B could mean easier reimbursement. The company outlined early plans for the launch of inclisiran after announcing it will buy The Medicines Company for $9.7bn.

Topic Business Strategies Deal trends Reimbursement

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。